NCT01278914已完成1 期
Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
Oslo University Hospital1 个研究点 分布在 1 个国家开始时间: 2002年2月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
PRIMARY OBJECTIVES:
Determination of safety and toxicity of vaccination with mRNA transfected DC (based on blood samples, and adverse events).
SECONDARY OBJECTIVES:
Determine immunological response to the vaccine (induction of specific T-cell response) and assessment of tumour response.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Must be at least 45 years of age.
- •Must have histologically confirmed adenocarcinoma of the prostate.
- •Must have evidence of disease progression while on LHRH agonist, or orchiectomy, with or without an antiandrogen for advanced prostate cancer. All patients will be maintained on the hormone regimen throughout this protocol that they were receiving at the time of entry or recent progression. Increasing PSA in three subsequent analysis.
- •Must be ambulatory with a ECOG performance score of <2
- •Lab.values as following :ANC ( 1.5 x 109/L; platelets ( 100 x 109/L, Hb ( 9 g/dL (( 5.6 mmol/L). Creatinine ( 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance ( 40 mL/min, Bilirubin < 20% above the upper limit of normal, ASAT and ALAT ( 2.5 the upper limit of normal. Albumin ( 2.5 g/L).
- •Prior radiotherapy: a minimum of 4 weeks (8 weeks in case of extensive prior radiotherapy) must have elapsed between the end of the prior radiotherapy and entry into the protocol.
- •Prior chemotherapy: a minimum of 4 weeks must have elapsed prior to entry in the study.
- •If the patient has received strontium-89 and alpha-radin, at least three months must have elapsed prior to entry in the study.
- •Informed consent and expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to the ICH-GCP Guidelines.
排除标准
- •History of prior malignancy other than prostate cancer, clinically evident within the 24 months preceding enrolment into the study, except curatively-treated basal cell or squamous cell carcinoma of the skin.
- •Active infection requiring antibiotic therapy.
- •Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.
- •Autoimmune disease treated with steroid(s)
- •History of asthma, anaphylaxis or other serious adverse reactions to vaccines.
- •History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis/dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.
- •Chemotherapy or other potentially immune-suppressive therapy that has been administered within 4 weeks prior to vaccination.
- •Impending untreated spinal cord compression or urinary outlet obstruction.
- •Any reason why, in the opinion of the investigator, the patient should not participate.
研究者
Svein Dueland
senior physician
Oslo University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant MelanomaMalignant MelanomaNCT01278940Oslo University Hospital31
进行中（未招募）
1 期
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant TumorsMalignant TumorsNCT05714748West China Hospital19
进行中（未招募）
1 期
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus InfectionHepatitis C InfectionChronic HepatitisHepatocellular CarcinomaNCT02772003National Cancer Institute (NCI)33
已完成
1 期
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryMetastatic Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Recurrent Malignant Peripheral Nerve Sheath TumorNCT02700230Mayo Clinic30
已完成
1 期
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by ElectroporationMelanoma (Skin)Intraocular MelanomaNCT00471133Ichor Medical Systems Incorporated24